Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00520-017-3979-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Following reduction of public health and social measures concurrent with SARS-CoV-2 Omicron emergence in late 2021 in Australia, COVID-19 case notification rates rose rapidly. As rates of direct viral testing and reporting dropped, true infection rates were most likely to be underestimated.
Objective: To better understand infection rates and immunity in this population, we aimed to estimate SARS-CoV-2 seroprevalence in Australians aged 0-19 years.
Comparative efficacy and safety of first-line tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and network meta-analysis.
Transl Cancer Res
July 2024
Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, China.
Background: Tyrosine kinase inhibitors (TKIs) have become the preferred drugs for the treatment of chronic phase (CP) chronic myeloid leukemia (CML). This study aims to compare the safety and efficacy of different TKIs as first-line treatments for CML using network meta-analysis (NMA), providing a basis for the precise clinical use of TKIs.
Methods: A systematic search was conducted on PubMed, Cochrane Library, Embase, China National knowledge Infrastructure (CNKI), Wanfang, Chinese Science and Technology Periodical Databases (VIP), SinoMed and ClinicalTrials.
Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review.
Front Pharmacol
June 2024
Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Article Synopsis
- Osimertinib is an effective treatment for lung cancer patients with EGFR mutations, but it can cause serious side effects like interstitial lung disease (ILD), leading to complications in treatment plans.
- This case study describes a 62-year-old male patient who developed severe ILD after starting osimertinib, but showed some improvement after aggressive treatment before being readmitted for recurrent ILD.
- The case highlights the need for careful assessment of ILD severity when considering the re-administration of osimertinib, as it can pose significant risks to patient health.
Investigating adherence to tyrosine kinase inhibitors in renal cancer.
J Oncol Pharm Pract
June 2024
Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Introduction: Tyrosine kinase inhibitors (TKIs) have been used as the first-line treatment for many patients with renal cell carcinoma (RCC), the seventh most common cancer in the United Kingdom. However, suboptimal adherence to TKIs can result in poor clinical prognosis. This study quantified RCC patients' adherence to TKIs and explored factors associated with suboptimal adherence.
View Article and Find Full Text PDFVorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects.
PLoS One
June 2024
EyePoint Pharmaceuticals, Inc., Watertown, Massachusetts, United States of America.
Purpose: Pathological angiogenesis and vascular instability are observed in diabetic retinopathy (DR), diabetic macular edema (DME), and wet age-related macular degeneration (wAMD). Many receptor tyrosine kinases (RTKs) including vascular endothelial growth factor receptors (VEGFRs) contribute to angiogenesis, whereas the RTK TIE2 is important for vascular stability. Pan-VEGFR tyrosine kinase inhibitors (TKIs) such as vorolanib, sunitinib, and axitinib are of therapeutic interest over current antibody treatments that target only one or two ligands.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!